Literature DB >> 16908120

Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman.

Thomas Elter1, Michal Sieniawski, Axel Gossmann, Claudia Wickenhauser, Ursula Schröder, Harald Seifert, Johannes Kuchta, Jürgen Burhenne, Klaus-Dieter Riedel, Gerd Fätkenheuer, Oliver A Cornely.   

Abstract

Invasive aspergillosis of the central nervous system has a mortality rate exceeding 90%. We describe a 29-year-old woman with a medical history of chronic polyarthritis who developed a proven rhinocerebral Aspergillus fumigatus infection refractory to first-line treatment with liposomal amphotericin B. The patient responded successfully to salvage combination treatment with voriconazole and caspofungin. Furthermore, for the first time, voriconazole levels in an intracerebral abscess were measured in this patient undergoing voriconazole oral therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16908120     DOI: 10.1016/j.ijantimicag.2006.04.006

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  13 in total

1.  The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis.

Authors:  S Schwartz; A Reisman; P F Troke
Journal:  Infection       Date:  2011-04-22       Impact factor: 3.553

2.  Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin.

Authors:  Laurent Arthur Decosterd; Bertrand Rochat; Benoît Pesse; Thomas Mercier; Frédéric Tissot; Nicolas Widmer; Jacques Bille; Thierry Calandra; Boris Zanolari; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

3.  Human tissue distribution of voriconazole.

Authors:  Stefan Weiler; David Fiegl; Róisín MacFarland; Eva Stienecke; Rosa Bellmann-Weiler; Stefan Dunzendorfer; Michael Joannidis; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

4.  Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring.

Authors:  Pier Giorgio Cojutti; Maria Merelli; Lorenzo Allegri; Giuseppe Damante; Matteo Bassetti; Federico Pea
Journal:  Br J Clin Pharmacol       Date:  2018-11-09       Impact factor: 4.335

Review 5.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

6.  In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid.

Authors:  Valentin Al Jalali; Robert Sauermann; Sabine Eberl; Markus Zeitlinger
Journal:  Infection       Date:  2019-02-06       Impact factor: 3.553

7.  Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy.

Authors:  Michael E Henry; Nicolas R Bolo; Chun S Zuo; Rosemond A Villafuerte; Kenroy Cayetano; Paul Glue; Bharat D Damle; Emma Andrews; Tara L Lauriat; Namoode S Rana; Jeffrey H Churchill; Perry F Renshaw
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

Review 8.  Tissue penetration of antifungal agents.

Authors:  Timothy Felton; Peter F Troke; William W Hope
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

9.  Voriconazole Induced Hallucinations and Visual Disturbances in a Female Child: A Case Report and Literature Review.

Authors:  Rujiang Zheng; Yu Li; Chuyi Guo; Yuxin Pei; Zhiyong Ke; Libin Huang
Journal:  Front Pediatr       Date:  2021-04-23       Impact factor: 3.418

10.  Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy.

Authors:  Ariane Leboime; Jean-Marie Berthelot; Yannick Allanore; Lama Khalil-Kallouche; Philippe Herman; Philippe Orcel; Frédéric Lioté
Journal:  Arthritis Res Ther       Date:  2009-11-03       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.